- Home
- MHLD vs DBVT Comparison
MHLD vs DBVT Comparison
Compare MHLD & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHLD
- DBVT
- Stock Information
- Founded
- MHLD 2007
- DBVT 2002
- Country
- MHLD Bermuda
- DBVT France
- Employees
- MHLD N/A
- DBVT N/A
- Industry
- MHLD Property-Casualty Insurers
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MHLD Finance
- DBVT Health Care
- Exchange
- MHLD Nasdaq
- DBVT Nasdaq
- Market Cap
- MHLD N/A
- DBVT 102.0M
- IPO Year
- MHLD 2008
- DBVT N/A
- Fundamental
- Price
- MHLD $1.25
- DBVT $9.84
- Analyst Decision
- MHLD
- DBVT Strong Buy
- Analyst Count
- MHLD 0
- DBVT 3
- Target Price
- MHLD N/A
- DBVT $13.67
- AVG Volume (30 Days)
- MHLD 195.3K
- DBVT 81.5K
- Earning Date
- MHLD 05-16-2025
- DBVT 04-30-2025
- Dividend Yield
- MHLD N/A
- DBVT N/A
- EPS Growth
- MHLD N/A
- DBVT N/A
- EPS
- MHLD N/A
- DBVT N/A
- Revenue
- MHLD $56,436,000.00
- DBVT $3,497,000.00
- Revenue This Year
- MHLD N/A
- DBVT $1,700.53
- Revenue Next Year
- MHLD N/A
- DBVT $535.67
- P/E Ratio
- MHLD N/A
- DBVT N/A
- Revenue Growth
- MHLD N/A
- DBVT N/A
- 52 Week Low
- MHLD $0.55
- DBVT $0.44
- 52 Week High
- MHLD $2.27
- DBVT $9.90
- Technical
- Relative Strength Index (RSI)
- MHLD 59.99
- DBVT 68.41
- Support Level
- MHLD $1.16
- DBVT $8.59
- Resistance Level
- MHLD $1.43
- DBVT $9.90
- Average True Range (ATR)
- MHLD 0.13
- DBVT 0.77
- MACD
- MHLD 0.00
- DBVT -0.02
- Stochastic Oscillator
- MHLD 63.27
- DBVT 91.04
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.